ECS Botanics (ASX:ECS) - Managing Director and Founder, Alex Keach
Managing Director and Founder, Alex Keach
Source: ECS Botanics
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • ECS Botanics’ (ECS) subsidiary secures a $4.9 million agreement to supply resin to Australian cannabis company, Cannvalate
  • The three-year binding agreement will begin following the installation of ECS’ extraction equipment at its tolling partner, Sun Pharmaceuticals’ facility, and will automatically renew on a yearly basis
  • The deal is expected to generate approximately $592,500 in revenue for ECS over the next 12 months
  • Company shares are up 5 per cent, trading at 3.2 cents

ECS Botanics’ (ECS) subsidiary has secured a $4.9 million agreement to supply resin to Australian cannabis company, Cannvalate.

Cannvalate holds one of Australia’s largest networks of medicinal cannabis prescribing doctors, and acts on behalf of The Valens Company in Australia to manufacture the product through Epsilon Healthcare (EPN).

The agreement with Cannvalate is expected to generate approximately $592,500 in revenue for ECS over the next 12 months.

The three-year binding agreement will begin following the installation of ECS’ extraction equipment at its tolling partner, Sun Pharmaceuticals’ facility, and will automatically renew on a yearly basis unless terminated.

ECS recently partnered with Sun Pharma in a supply and tolling agreement to accelerate plans for the cultivation and extraction of competitively priced cannabis oils.

“This agreement further highlights ECS’ attractiveness as a supply chain partner to both global and local companies,” said Executive General Manager, Nan-Maree Schoerie.

“We are delighted that Cannvalate, and their partner Valens, have selected ECS as their resin supplier and look forward to a long and rewarding relationship.”

ECS Botanics said it expects the Therapeutic Goods Administration will enforce stricter quality standards on imported medicinal cannabis products as of March 2022. As such, the playing field will level for domestic manufacturers compared to importers, which will result in demand for Australian grown products increasing over the next year.

Company shares were up 5 per cent, trading at 3.2 cents at 11:58 am AEDT.

ECS by the numbers
More From The Market Herald
Little Green Pharma (ASX:LGP) - Managing Director, Fleta Solomon

" Little Green Pharma (ASX:LGP) seeks to expand to Greece

Little Green Pharma (ASX:LGP) seeks to expand to Greece
Orexplore Technologies (ASX:OXT) - Chair, Dr Alan Bye

" Orexplore Technologies (ASX:OXT) debuts on ASX

Mineral scanning technology company Orexplore Technologies (ASX:OXT) has commenced trading on the ASX today under the…
Frontier Digital Ventures (ASX:FDV) - Founder and CEO, Shaun DiGregorio

" Frontier Digital Ventures (ASX:FDV) completes $18.9m SPP

Frontier Digital Ventures (ASX:FDV) completes a share purchase plan (SPP) with applications totalling approximately $18.9 million,…
Technology Metals (ASX:TMT) - Managing Director, Ian Prentice

" Technology Metals (ASX:TMT) expands MoU for vanadium redox flow batteries

Technology Metals (ASX:TMT) is set to expand a memorandum of understanding which was first executed in…